Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Operations (2022 - 2025)

Axsome Therapeutics' Cash from Operations history spans 4 years, with the latest figure at 18653000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 28.81% year-over-year to 18653000.0; the TTM value through Dec 2025 reached 93405000.0, up 27.26%, while the annual FY2025 figure was 93405000.0, 27.26% up from the prior year.
  • Cash from Operations for Q4 2025 was 18653000.0 at Axsome Therapeutics, down from 1046000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1046000.0 in Q3 2025 and bottomed at 55349000.0 in Q2 2023.
  • The 4-year median for Cash from Operations is 30236000.0 (2023), against an average of 30212875.0.
  • The largest annual shift saw Cash from Operations crashed 818.52% in 2024 before it skyrocketed 105.61% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 27563000.0 in 2022, then dropped by 10.15% to 30362000.0 in 2023, then grew by 13.7% to 26202000.0 in 2024, then increased by 28.81% to 18653000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Cash from Operations are 18653000.0 (Q4 2025), 1046000.0 (Q3 2025), and 32423000.0 (Q2 2025).